U.S. markets close in 38 minutes
  • S&P 500

    3,815.93
    -9.40 (-0.25%)
     
  • Dow 30

    30,857.26
    -240.00 (-0.77%)
     
  • Nasdaq

    11,263.13
    +135.29 (+1.22%)
     
  • Russell 2000

    1,726.95
    -0.80 (-0.05%)
     
  • Crude Oil

    99.76
    -8.67 (-8.00%)
     
  • Gold

    1,766.90
    -34.60 (-1.92%)
     
  • Silver

    19.20
    -0.46 (-2.35%)
     
  • EUR/USD

    1.0261
    -0.0164 (-1.57%)
     
  • 10-Yr Bond

    2.8090
    -0.0800 (-2.77%)
     
  • GBP/USD

    1.1948
    -0.0156 (-1.29%)
     
  • USD/JPY

    135.7780
    +0.1180 (+0.09%)
     
  • BTC-USD

    20,171.42
    +330.74 (+1.67%)
     
  • CMC Crypto 200

    435.74
    -4.28 (-0.97%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,423.47
    +269.66 (+1.03%)
     

Harmony Biosciences Holdings (NASDAQ:HRMY) rallies 19% this week, taking one-year gains to 40%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It might be of some concern to shareholders to see the Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) share price down 19% in the last month. But looking back over the last year, the returns have actually been rather pleasing! In that time we've seen the stock easily surpass the market return, with a gain of 40%.

The past week has proven to be lucrative for Harmony Biosciences Holdings investors, so let's see if fundamentals drove the company's one-year performance.

See our latest analysis for Harmony Biosciences Holdings

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

During the last year Harmony Biosciences Holdings grew its earnings per share, moving from a loss to a profit.

When a company is just on the edge of profitability it can be well worth considering other metrics in order to more precisely gauge growth (and therefore understand share price movements).

However the year on year revenue growth of 66% would help. We do see some companies suppress earnings in order to accelerate revenue growth.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. This free report showing analyst forecasts should help you form a view on Harmony Biosciences Holdings

A Different Perspective

Harmony Biosciences Holdings boasts a total shareholder return of 40% for the last year. The more recent returns haven't been as impressive as the longer term returns, coming in at just 4.7%. Having said that, we doubt shareholders would be concerned. It seems the market is simply waiting on more information, because if the business delivers so will the share price (eventually). I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Harmony Biosciences Holdings is showing 2 warning signs in our investment analysis , you should know about...

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.